Researchers have developed silica spheres to contain cancer therapeutics that melt at certain temperatures and have the potential to improve drug delivery.
The Mundipharma network of independent associated companies has purchased worldwide development, commercialisation and production rights to CAP7.1 from CellAct for more than $250m.